press release investor nutraceuticals science eXoZymes advancing commercial readiness with profound production metrics on initial NCT pilot run Jan 29, 2026 7:35:27 PM
investor press clippings video Beryl Elites: Interview with Capital Markets Advisor, Sanjeev Srivastava Jan 8, 2026 9:29:00 AM
heltzen investor press clippings video Beryl Elites: What is Artificial Evolution - an interview with CEO Heltzen Jan 7, 2026 10:23:05 AM
investor nutraceuticals medicine press clippings International Business Times: AI meets enzymes - eXoZymes enables high-yield production of compounds previously impossible to make Dec 17, 2025 9:27:09 AM
heltzen investor press clippings Beryl Elites: AI's Billion-dollar Bet on Life Sciences - From Drug Discovery to Patient Impact (panel) Dec 15, 2025 9:49:43 AM
press release investor nutraceuticals medicine eXoZymes achieves 100× scale-up of NCT production using exozymes, demonstrating near-perfect feedstock conversion Dec 11, 2025 4:08:55 PM
investor nutraceuticals medicine press clippings LA Weekly: The Enzyme Frontier - eXoZymes Unlocks a New Era for Cannabinoid Nutraceuticals and Pharma Nov 20, 2025 9:15:00 AM
investor press clippings Slack Capital report: EXOZ is a once-in-a-lifetime opportunity Nov 19, 2025 9:15:00 AM
heltzen investor nutraceuticals medicine press clippings video 'The Upside' interview: Michael Heltzen & Lou Basenese Nov 18, 2025 4:18:19 PM
.jpg?width=1024&height=1024&name=NCT-for-testing(edit).jpg)
